Bank of America Corp DE increased its stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 376.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,273,442 shares of the company's stock after buying an additional 3,376,446 shares during the period. Bank of America Corp DE owned 6.04% of Ventyx Biosciences worth $9,359,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in VTYX. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Ventyx Biosciences by 88.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 871,527 shares of the company's stock valued at $1,909,000 after purchasing an additional 409,357 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Ventyx Biosciences by 99.1% in the 4th quarter. Renaissance Technologies LLC now owns 624,500 shares of the company's stock valued at $1,368,000 after acquiring an additional 310,800 shares during the period. Boothbay Fund Management LLC raised its position in shares of Ventyx Biosciences by 472.2% in the 4th quarter. Boothbay Fund Management LLC now owns 314,891 shares of the company's stock valued at $690,000 after acquiring an additional 259,863 shares during the period. Monaco Asset Management SAM acquired a new stake in shares of Ventyx Biosciences in the 4th quarter valued at approximately $526,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of Ventyx Biosciences in the 4th quarter valued at approximately $436,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.
Ventyx Biosciences Trading Up 2.0%
Shares of NASDAQ:VTYX traded up $0.04 during mid-day trading on Wednesday, reaching $1.80. The stock had a trading volume of 808,276 shares, compared to its average volume of 1,335,718. The firm has a market cap of $127.73 million, a PE ratio of -0.76 and a beta of 0.73. The firm has a 50 day simple moving average of $1.23 and a two-hundred day simple moving average of $1.73. Ventyx Biosciences, Inc. has a twelve month low of $0.78 and a twelve month high of $5.66.
Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.09. On average, equities analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.
About Ventyx Biosciences
(
Free Report)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
See Also
Before you consider Ventyx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.
While Ventyx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
